Product ID: 309119
Reminder: The pictures are all real shots on this site and are for reference only; if there may be a delay in the launch of new packaging, please refer to the actual product.
Venclexta is a prescribed medicine used to treat persons who small lymphocytic lymphoma (SLL).
India Direct Mail
Venetoclax is used to treat some kinds of chronic lymphocytic leukemia ( cancer in white blood cells) and (SLL; a type of cancer that begins mainly in the lymph nodes). This drug can be given alone or in combination with obinutuzumab (Gazyva) or rituximab (Rituxan) azacitidine (Vidaza), decitabine (Dacogen), or cytarabine as a first-line treatment for AML acute myeloid leukemia (cancer in the white blood cells ) in people 75 and up or in adults with medical conditions that prevent them from receiving other chemotherapy medications. Venetoclax belongs to a group of drugs known as B-cell lymphoma-2 (BCL-2) inhibitors. It works by preventing a protein in the body from assisting cancer cells in survival. This aids in the killing of cancer cells.
How Venclyxto Works?
Venetoclax, the active ingredient in Venclyxto, binds to the Bcl-2 protein. High concentrations of this protein are seen in leukaemia cancer cells, where they enable the cells to live longer in the body and become resistant to cancer treatments. Venetoclax kills cancer cells by binding to Bcl-2 and inhibiting its functions, which inhibits the development of the illness.
The major advantage of Venclyxto is that it can be taken with or without radiotherapy. This restores a white blood cell count. It also allows the patient to undergo treatment for leukaemia and various immunotherapy drugs, such as rituximab and obinutuzumab. As a result, the immune system can fight cancer cells more effectively in the body. Moreover, patients who do not respond well to rituximab or another immunotherapy drug may find that Venclyxto is more effective in helping them beat their cancer. Venclyxto can also be taken at the same time as other treatments for leukaemia. This ensures patients receive all treatment, in the most effective manner, regarding their condition. It is also a very high quality medication that is noted for being well tolerated.
Only those with a valid prescription may purchase Venclyxto, which should be begun and managed by a physician with knowledge in cancer medications. It is offered in tablet form (10, 50, and 100 mg), to be ingested once daily with food.
The starting dose of Venclyxto Capsules for CLL is 20 mg per day, and over the course of five weeks, the dose is gradually increased to 400 mg per day. The length of the treatment depends on the medication it is given with, and it is then continued at a dose of 400 mg daily. Venclyxto is administered as long as the medication is effective when administered alone. For AML, a 100 mg initial dose is increased over three days to 400 mg per day. If specific side effects arise, it might be necessary to lower the dose or stop the medication altogether.
The most common serious side effects were anaemia and reduced neutrophils. In AML, the most common side effects of Venclyxto used in combination with azacitidine are pneumonia, sepsis (blood poisoning), urinary tract infection (infection of the structures that carry urine), neutropenia (low levels of neutrophils, a type of white blood cells) with or without fever, anaemia, thrombocytopenia (low levels of blood platelets), hypokalaemia (low levels of potassium), decreased appetite, dizziness, headache, nausea, diarrhoea, vomiting, stomatitis (inflammation of the lining of the mouth), abdominal pain, joint pain, weakness, tiredness, decreased weight and increased blood bilirubin levels (high blood levels of bilirubin, a breakdown product of red blood cells, which can cause yellowing of the skin and eyes).
The most frequent significant side effects are bleeding, sepsis, anaemia, thrombocytopenia, hypokalaemia, pneumonia, and neutropenia with or without fever.